Fisher Asset Management LLC Buys 253,808 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Fisher Asset Management LLC lifted its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 210.6% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 374,352 shares of the biopharmaceutical company's stock after acquiring an additional 253,808 shares during the quarter. Fisher Asset Management LLC owned approximately 0.56% of Celldex Therapeutics worth $12,724,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently made changes to their positions in the company. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Celldex Therapeutics in the 2nd quarter valued at $76,000. KBC Group NV raised its holdings in shares of Celldex Therapeutics by 31.2% during the third quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company's stock valued at $71,000 after purchasing an additional 495 shares during the period. CANADA LIFE ASSURANCE Co boosted its position in shares of Celldex Therapeutics by 26.4% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 4,570 shares of the biopharmaceutical company's stock worth $192,000 after purchasing an additional 955 shares in the last quarter. Los Angeles Capital Management LLC grew its stake in Celldex Therapeutics by 9.5% in the second quarter. Los Angeles Capital Management LLC now owns 7,371 shares of the biopharmaceutical company's stock valued at $273,000 after acquiring an additional 638 shares during the period. Finally, Quest Partners LLC increased its holdings in shares of Celldex Therapeutics by 1,364.9% during the second quarter. Quest Partners LLC now owns 7,383 shares of the biopharmaceutical company's stock valued at $273,000 after acquiring an additional 6,879 shares in the last quarter.

Analysts Set New Price Targets

CLDX has been the subject of a number of recent research reports. Citigroup initiated coverage on shares of Celldex Therapeutics in a research note on Monday, October 7th. They set a "buy" rating and a $70.00 price target for the company. The Goldman Sachs Group initiated coverage on shares of Celldex Therapeutics in a report on Monday, September 30th. They issued a "neutral" rating and a $45.00 target price on the stock. HC Wainwright reissued a "buy" rating and set a $80.00 price objective on shares of Celldex Therapeutics in a report on Wednesday, November 20th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $67.00 target price on shares of Celldex Therapeutics in a research report on Monday, September 16th. Finally, Wolfe Research lowered Celldex Therapeutics from an "outperform" rating to a "peer perform" rating in a research report on Friday, September 27th. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $62.25.

Insider Buying and Selling

In related news, CEO Anthony S. Marucci acquired 11,500 shares of the company's stock in a transaction that occurred on Monday, November 11th. The shares were acquired at an average price of $26.82 per share, with a total value of $308,430.00. Following the acquisition, the chief executive officer now owns 40,284 shares of the company's stock, valued at approximately $1,080,416.88. This trade represents a 39.95 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 3.80% of the stock is currently owned by corporate insiders.

Celldex Therapeutics Price Performance

Shares of Celldex Therapeutics stock traded up $1.13 during trading hours on Thursday, hitting $27.89. 766,814 shares of the company's stock traded hands, compared to its average volume of 886,809. The stock has a market capitalization of $1.85 billion, a price-to-earnings ratio of -10.85 and a beta of 1.60. Celldex Therapeutics, Inc. has a 12-month low of $22.93 and a 12-month high of $53.18. The company has a fifty day simple moving average of $29.35 and a 200-day simple moving average of $34.60.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.